Value-Based Medication Benefits in Diabetes Management

By Staff Writer

February 9, 2024

Introduction

Type 2 diabetes (T2D) is a complex condition that involves inadequate insulin production and irregular blood sugar levels. Over the past two decades, the prevalence of T2D has surged from 10% to 13% in the United States alone. Pharmacotherapy plays a crucial role in managing diabetes and preventing secondary complications. These complications are becoming more prevalent in the working age population. However, the rising costs of medication present a significant barrier to optimal care. In particular for lower-income patients, leading to high out-of-pocket (OOP) payments and non-compliance.

Value-Based Medication Benefits

The average OOP for patients diagnosed with diabetes are between $150 to $500 per year for treatment. To counter the issue of escalating OOP costs, some employers have adopted more generous health insurance designs and policies to counter additional payments. One such initiative is the preventive drug list (PDL) add-on. PDLs allows patients to pay reduced co-payments or deductible amounts for high-value preventive medications, including antidiabetic drugs.

Impact of PDLs on Diabetes Management

Recent studies have found that PDLs are associated with increased preventive medication fills among diabetes patients from lower-income neighbourhoods. On the other hand, there has been a shortage of research that has investigated the correlation between value-based drug benefits and health outcomes.

A recent study from Duke University aimed to address this gap by studying whether PDLs are associated with reduced rates of acute, preventable diabetes complications. The study examined a dataset spanning a 14-year period (2004-2017) and consisting of almost 2.3 million people with diabetes who were covered by commercial insurance.

Key Findings

Patients with diabetes enrolled in a value-based medication benefit increased their antidiabetic medication use. They also experienced 8.4% fewer acute, diabetes complication days compared to controls. Notably, PDL members from lower-income areas, who experienced the largest magnitude increases in antidiabetic medication use, experienced a 10.2% decline in complication days. To the authors knowledge no other studies have been published that examined reduced medication costs in diabetes and its effects. However, in two randomised clinical trials conducted in Canada, it was discovered that the removal of drug co-payments resulted in slight to moderate increases in medication usage.

Limitations and Future Research

While the findings from this study are promising, they are not without limitations, as it only applies to patients with diabetes on commercial health plans. Further, PDL coverage was not randomly assigned, but chosen by certain employers. Finally, the study only examined outcomes associated with PDL enrollment over a single year. For more comprehensive research, larger sample sizes will be necessary to include additional clinical outcomes.

Conclusion

In conclusion, this study indicates that value-based medication benefits not only lowers antidiabetic medication OOP costs, but also shows a 8.4% reduction in preventable diabetes complications. The study results might suggest a strategy that entails incentivising the adoption of targeted cost-sharing reductions. Especially, among commercially insured patients with diabetes and lower income to enhance health outcomes.

 

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.